logo
Plus   Neg
Share
Email

Novartis: Tasigna Long Term Trial Patients Maintain Treatment-free Remission

Novartis (NVS) said long-term data from the ongoing ENESTfreedom and ENESTop trials showed sustained treatment-free remission after stopping frontline and second-line Tasigna therapy in patients with Ph+ chronic myeloid leukemia.

The company also presented study results showing encouraging results for asciminib, an investigational allosteric BCR-ABL inhibitor, in combination with three different tyrosine kinase inhibitors in heavily pre-treated Ph+ chronic myeloid leukemia in the chronic phase.

The company will present the study results at the 24th Congress of the European Hematology Association in Amsterdam.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google on Wednesday announced new restrictions on political advertisers around the world. The company has joined Twitter in revising its political ad rules ahead of the election season British luxury car giant Aston Martin unveiled its first SUV at an event in Los Angeles and at a simultaneous event in Beijing. The DBX SUV comes with an aluminium body with a typical Aston Martin grille flanked by LED headlights with LED DRLs. "I can't emphasize enough how incredibly exciting... Google has rolled out an audio news service for Google Assistant, called 'Your News Update,' which will read out a user's customized news feed. According to the tech giant, 'Your News Update' is a smarter way to listen to the news hosted by the Google Assistant. The customized news feed will deliver stories from a variety of media partners, including CBS, Politico, Fox News and CNN.
Follow RTT
>